Arbutus Biopharma has been granted a patent for nucleic acids, specifically double-stranded siRNA molecules, and their conjugates designed to target the liver. These innovations aim to treat liver diseases, including hepatitis B and D, and include methods for synthesizing these conjugates. GlobalData’s report on Arbutus Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Arbutus Biopharma, Peptide pharmacophores was a key innovation area identified from patents. Arbutus Biopharma's grant share as of June 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Liver-targeting sirna conjugates for treating hepatitis diseases
The granted patent US12043833B2 outlines a series of claims related to a specific compound and its applications, particularly in the context of treating hepatitis B viral infections. The primary claim describes a compound that includes various small interfering RNA (siRNA) molecules, specifically identified by their respective sequence IDs. The patent details a total of 37 distinct siRNA molecules, which can be utilized in the formulation of the compound. Additionally, the claims encompass pharmaceutical compositions that combine these compounds or their pharmaceutically acceptable salts with suitable carriers for effective delivery.
Furthermore, the patent delineates methods for administering the siRNA compounds to the liver of a human, emphasizing their therapeutic potential against hepatitis B. Claims also specify the use of particular siRNA molecules, such as siRNA 3, 10, 15, 20, and 25, among others, in the formulation of pharmaceutical compositions. This comprehensive approach not only highlights the versatility of the siRNA compounds but also underscores their potential role in targeted therapies for viral infections, particularly hepatitis B, through effective delivery mechanisms.
To know more about GlobalData’s detailed insights on Arbutus Biopharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
